The HIPPORAD study is a phase II trial for patients with 4 – 10 brain metastases from solid tumors. The purpose of this study is to evaluate the benefits of whole brain radiation therapy (WBRT) with hippocampal sparing (HA) and boost to metastases on memory performance and morphologic brain changes compared to WBRT and concurrent boost without HA.

Primary endpoint: neurocognitive function at 3 months, measurement of learning performance (Verbal Learning and Memory Test) 3 months after radiotherapy compared to baseline.

Secondary endpoints: MRI morphological changes, local tumor control, occurrence of new brain metastases (especially in hippocampal regions), overall survival, the number of patients who died due to brain metastases, local progression-free survival, depression, changes in cognitive function at different time points after treatment compared to baseline, quality of life.